May 17, 2020

UCL Technology Fund investment MeiraGTx raises $75mn

pharmaceutical
Genetics
pharmaceutical
Genetics
Catherine Sturman
2 min
UCL Technology Fund has announced that one of its investments, MeiraGTx Holdings plc, a vertically integrated, clinical stage gene therapy company, has...

UCL Technology Fund has announced that one of its investments, MeiraGTx Holdings plc, a vertically integrated, clinical stage gene therapy company, has raised $75 million of gross proceeds upon the close of its initial public offering (IPO), selling 5,000,000 shares.

The UCL Technology Fund (UCLTF) is managed by Albion Capital in collaboration with UCL Business (UCLB) and is dedicated to bringing UCL’s world-class research in life and physical sciences to commercial reality. MeiraGTx is its first investment to IPO.

MeiraGTx has strong roots in UCL; its rare eye diseases business was borne out of the laboratories of Professor Robin Ali, a human molecular genetics expert at the UCL Institute of Ophthalmology, a world leader in ocular gene therapy.

MeiraGTx is developing therapies for diseases of the eye, salivary glands and central nervous system. Its expertise in viral vector design and optimisation, advanced gene therapy manufacturing, and technology providing temporal control of gene therapies, has the potential to transform the gene therapy landscape.

See also

Based in London and New York, the company has four ongoing clinical programmes, one compassionate use programme and a broad pipeline of preclinical and research programmes.

Funds raised from the IPO will enable MeiraGTx to progress its product candidates to treat inherited rare eye diseases, xerostomia (‘dry mouth’) and neurodegenerative diseases.

Founded in the UK in 2015 in a series of deals which combined the assets and expertise of MeiraGTx and UCLB spinout Athena Vision, Athena Vision was created by UCLB, who owned the rights and options to Professor Robin Ali’s and team’s ophthalmic gene therapy programmes. The UCL Technology Fund first supported MeiraGTx as part of a $70mn Series B investment round in 2017 to fund the continuation of its clinical trials. 

“MeiraGTx is revolutionising the treatment of ocular, nerve and salivary gland diseases with highly specialised, flexible gene therapies which have the potential to dramatically decrease morbidity and improve quality of life,” said Christoph Ruedig, partner at Albion Capital.

“We are impressed by the way the company combines cutting-edge science, a nimble platform and state-of-the-art manufacturing processes to deliver life-changing gene treatments. We look forward to supporting the business’s ongoing development through the next stage of its journey as a public company.”

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article